ALKEM2023-01-012023-03-31 ALKEM2023-01-012023-03-31 ALKEM2023-01-012023-03-31in-bse-fin:OneOperatingExpenses01Member ALKEM2023-01-012023-03-31in-bse-fin:FourOperatingExpenses01Member ALKEM2023-03-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 539523 ALKEM NOTLISTED Alkem Laboratories Limited Equity 2022-04-01 2023-03-31 2023-05-19 2023-05-09 INR Millions Yearly 11:00:00 13:30:00 2023-05-19 2023-05-19 true Cash Flow Indirect Declaration of unmodified opinion Single segment The Company is exclusively engaged in pharmaceutical business 2023-01-01 2023-03-31 Audited Standalone 22379900000.00 766000000.00 23145900000.00 6588800000.00 2349800000.00 449200000.00 3464000000.00 217400000.00 571600000.00 6208200000.00 19849000000.00 3296900000.00 0.00 3296900000.00 536300000.00 212700000.00 749000000.00 0.00 2547900000.00 0.00 0.00 0.00 0.00 2547900000.00 -9600000.00 2538300000.00 0.00 0.00 239100000.00 2 21.31 21.31 0.00 0.00 21.31 21.31 1. The above audited standalone financial results of the Company were reviewed and recommended by the Audit Committee on 18 May 2023 and subsequently approved by the Board of Directors at its meeting held on 19 May 2023. The auditors have expressed an unmodified opinion on the financial results for the year ended 31 March 2023. The figures for the quarter ended 31 March 2023 and 31 March 2022 are balancing figures between audited figures in respect of the full financial year and the unaudited published year-to-date figures up to the third quarter ended 31 December 2022 and 31 December 2021 respectively, which were subjected to limited review. 2. The Company has entered into a Securities Subscription Agreement and Shareholders’ Agreement dated 23 December 2022 with Enzene Biosciences Limited, a subsidiary of the Company (“Enzene”), Eight Roads Ventures India Healthcare IV, L.P. (“Eight Roads Ventures”) and F-Prime Capital Partners Life Sciences Fund VI LP (“F-Prime Capital”) towards subscription of Compulsorily Convertible Preference Shares (‘CCPS’) by Eight Roads Ventures and F-Prime Capital in Enzene for a consideration of Rs.1,614.8 million which is equivalent to 8% of the subsidiary’s equity valuation. 3. During the quarter ended 31 March 2023, the Company has paid a Special Dividend of Rs. 25 (Rupees Twenty five only) per equity share. In addition to the Special Dividend, the Company has also paid an interim dividend of Rs. 15 (Rupees Fifteen only) per equity share amounting to a total interim dividend of Rs. 40 (Rupees Forty only) per equity share (2000% on the face value of Rs. 2 each) for the financial year ended 31 March 2023. The Board of Directors at its meeting held on 19 May 2023 has recommended a final dividend of Rs. 10 (Rupees Ten only) per equity share (500% on the face value of Rs. 2 each) for the financial year 2022-23. 4. The Company operates in one reportable business segment i.e. Pharmaceuticals , accordingly no separate disclosure of segment has been made. Single segment 2022-04-01 2023-03-31 Audited Standalone 90545500000.00 2662900000.00 93208400000.00 26297800000.00 9431300000.00 2577300000.00 15162200000.00 864000000.00 2298500000.00 23307400000.00 79938500000.00 13269900000.00 0.00 13269900000.00 2275200000.00 -350000000.00 1925200000.00 0.00 11344700000.00 0.00 0.00 0.00 0.00 11344700000.00 -21900000.00 11322800000.00 0.00 0.00 239100000.00 2 93259400000.00 94.88 94.88 0.00 0.00 94.88 94.88 Other expenses 6208200000.00 Other expenses 23307400000.00 16725200000.00 1851000000.00 0.00 1525687000.00 436500000.00 26929600000.00 83400000.00 309400000.00 27322400000.00 10849200000.00 880100000.00 59590087000.00 17246600000.00 3125900000.00 17683400000.00 50100000.00 21588600000.00 16800000.00 1683600000.00 44148400000.00 6327113000.00 67722113000.00 127312200000.00 239100000.00 93259400000.00 93498500000.00 93498500000.00 450600000.00 450600000.00 2841700000.00 73100000.00 3365400000.00 11366300000.00 10763400000.00 4904200000.00 27033900000.00 1170000000.00 2159400000.00 85000000.00 30448300000.00 33813700000.00 127312200000.00 1. The above audited standalone financial results of the Company were reviewed and recommended by the Audit Committee on 18 May 2023 and subsequently approved by the Board of Directors at its meeting held on 19 May 2023. The auditors have expressed an unmodified opinion on the financial results for the year ended 31 March 2023. The figures for the quarter ended 31 March 2023 and 31 March 2022 are balancing figures between audited figures in respect of the full financial year and the unaudited published year-to-date figures up to the third quarter ended 31 December 2022 and 31 December 2021 respectively, which were subjected to limited review. 2. The Company has entered into a Securities Subscription Agreement and Shareholders’ Agreement dated 23 December 2022 with Enzene Biosciences Limited, a subsidiary of the Company (“Enzene”), Eight Roads Ventures India Healthcare IV, L.P. (“Eight Roads Ventures”) and F-Prime Capital Partners Life Sciences Fund VI LP (“F-Prime Capital”) towards subscription of Compulsorily Convertible Preference Shares (‘CCPS’) by Eight Roads Ventures and F-Prime Capital in Enzene for a consideration of Rs.1,614.8 million which is equivalent to 8% of the subsidiary’s equity valuation. 3. During the quarter ended 31 March 2023, the Company has paid a Special Dividend of Rs. 25 (Rupees Twenty five only) per equity share. In addition to the Special Dividend, the Company has also paid an interim dividend of Rs. 15 (Rupees Fifteen only) per equity share amounting to a total interim dividend of Rs. 40 (Rupees Forty only) per equity share (2000% on the face value of Rs. 2 each) for the financial year ended 31 March 2023. The Board of Directors at its meeting held on 19 May 2023 has recommended a final dividend of Rs. 10 (Rupees Ten only) per equity share (500% on the face value of Rs. 2 each) for the financial year 2022-23. 4. The Company operates in one reportable business segment i.e. Pharmaceuticals , accordingly no separate disclosure of segment has been made. 863991000.00 2510700000.00 19162000.00 0.00 0.00 -838497000.00 0.00 0.00 0.00 82663000.00 0.00 0.00 0.00 2298500000.00 0.00 282995000.00 0.00 0.00 0.00 -485228000.00 36300000.00 1471779000.00 0.00 0.00 0.00 0.00 119717000.00 0.00 0.00 3345924000.00 16615824000.00 0.00 0.00 0.00 2241623000.00 0.00 14374201000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 27570000.00 1417763000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1687910000.00 0.00 0.00 0.00 0.00 0.00 36300000.00 1229520000.00 0.00 3782683000.00 0.00 1970400000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -11029506000.00 0.00 0.00 126213000.00 5260900000.00 696081000.00 0.00 0.00 -17112700000.00 -768099000.00 0.00 -768099000.00 818200000.00 50101000.00 -14800000.00 -33700000.00 -5200000.00 -11800000.00